Disulfide-rich peptides as next-generation radiopharmaceuticals

Peptides are emerging as a preferred targeting agent for many radiopharmaceutical targets due to several favourable characteristics, including high tissue penetration and target specificity. Among them, disulfide-rich peptides stand out for their exceptional intrinsic stability, making them particularly well-suited for further development in this field – yet they remain underexplored. This review highlights examples where disulfide-rich peptides have been used in radiopharmaceuticals for imaging and therapy. We compare them to recently approved peptide radiopharmaceuticals to provide context and support for the broader use of disulfide-rich peptides for targeted delivery of radiation. Future directions are also discussed, including how emerging technologies can be applied to the discovery of new disulfide-rich peptide radiopharmaceuticals.

• Publication year

  2025

• Venue

  Australian journal of chemistry (Print)

• Publication date

  2025-11-10

• Fields of study

  Not labeled

• Identifiers
  DOI 10.1071/ch25096
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Top companies and drugs by sales in 2024

  2025cited by this paper
• Radiopharmaceuticals and their applications in medicine

  2025cited by this paper
• Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platform

  2024cited by this paper
• Display Technologies for Expanding the Pharmaceutical Applications of Cyclotides

  2024cited by this paper
• Native and Engineered Cyclic Disulfide-Rich Peptides as Drug Leads

  2023cited by this paper
• Therapeutic Antibodies in Medicine

  2023cited by this paper
• Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer.

  2023cited by this paper
• CXCR4-Targeted Radiopharmaceuticals for the Imaging and Therapy of Malignant Tumors

  2023cited by this paper
• An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy

  2023cited by this paper
• Peptides as multifunctional players in cancer therapy

  2023cited by this paper
• Mini review of first-in-human integrin αvβ6 PET tracers

  2023cited by this paper
• Role of Somatostatin Signalling in Neuroendocrine Tumours

  2022cited by this paper
• Directed evolution identifies high-affinity cystine-knot peptide agonists and antagonists of Wnt/β-catenin signaling

  2022cited by this paper
• Radiolabeled Somatostatin Analogs—A Continuously Evolving Class of Radiopharmaceuticals

  2022cited by this paper
• Ex silico engineering of cystine-dense peptides yielding a potent bispecific T cell engager

  2022cited by this paper
• Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy

  2022cited by this paper
• 68Ga-Pentixafor PET/CT for Detection of Chemokine Receptor CXCR4 Expression in Myeloproliferative Neoplasms

  2021cited by this paper
• Trends in peptide drug discovery

  2021cited by this paper
• Linking molecular evolution to molecular grafting

  2021cited by this paper
• Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study

  2021cited by this paper
• Optimized serum stability and specificity of an αvβ6 integrin-binding peptide for tumor targeting

  2021cited by this paper
• Pilot-phase PET/CT study targeting integrin αvβ6 in pancreatic cancer patients using the cystine-knot peptide–based 18F-FP-R01-MG-F2

  2021cited by this paper
• An Ultrapotent and Selective Cyclic Peptide Inhibitor of Human β-Factor XIIa in a Cyclotide Scaffold.

  2021cited by this paper
• Rational Design of Potent Peptide Inhibitors of the PD-1:PD-L1 Interaction for Cancer Immunotherapy.

  2021cited by this paper
• Improving Tumor Penetration of Antibodies and Antibody–Drug Conjugates: Taking Away the Barriers for Trojan Horses

  2021cited by this paper
• Biodistribution and internal radiation dosimetry of a companion diagnostic radiopharmaceutical, [68Ga]PSMA-11, in subcutaneous prostate cancer xenograft model mice

  2021cited by this paper
• Approaches for peptide and protein cyclisation

  2021cited by this paper
• Mammalian Surface Display Screening of Diverse Cystine-Dense Peptide Libraries for Difficult-to-Drug Targets.

  2020cited by this paper
• Cysteine‐Rich Peptides: Hyperstable Scaffolds for Protein Engineering

  2020cited by this paper
• Radiopharmaceutical therapy in cancer: clinical advances and challenges

  2020cited by this paper
• Methods to Enhance the Metabolic Stability of Peptide-Based PET Radiopharmaceuticals

  2020cited by this paper
• Comparative evaluation of 68Ga-labelled TATEs: the impact of chelators on imaging

  2020cited by this paper
• Development of therapeutic antibodies for the treatment of diseases

  2020cited by this paper
• Bioactive Cyclization Optimizes the Affinity of a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Peptide Inhibitor.

  2020cited by this paper
• Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention

  2019cited by this paper
• Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial.

  2019cited by this paper
• Non-covalent albumin-binding ligands for extending the circulating half-life of small biotherapeutics.

  2019cited by this paper
• Evaluation of integrin αvβ6 cystine knot PET tracers to detect cancer and idiopathic pulmonary fibrosis

  2019cited by this paper
• Cyclotides: From Structure to Function.

  2019cited by this paper
• Therapeutic Radiopharmaceuticals Targeting Integrin αvβ6

  2018cited by this paper
• Method to generate highly stable D-amino acid analogs of bioactive helical peptides using a mirror image of the entire PDB

  2018cited by this paper
• A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts

  2018cited by this paper
• Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein

  2018cited by this paper
• Designing macrocyclic disulfide-rich peptides for biotechnological applications

  2018cited by this paper
• Preparation of 68Ga-PSMA-11 with a Synthesis Module for Micro PET-CT Imaging of PSMA Expression during Prostate Cancer Progression

  2018cited by this paper
• Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With 177Lu-Dotatate in the Phase III NETTER-1 Trial.

  2018cited by this paper
• Effects of adding an albumin binder chain on [177Lu]Lu-DOTATATE.

  2018cited by this paper
• In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent.

  2017cited by this paper
• Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors

  2017cited by this paper
• Preclinical evaluation of [68Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [68Ga]pentixafor

  2016cited by this paper
• Engineered knottin peptides as diagnostics, therapeutics, and drug delivery vehicles.

  2016cited by this paper
• Pharmacological Characterization of the αvβ6 Integrin Binding and Internalization Kinetics of the Foot-and-Mouth Disease Virus Derived Peptide A20FMDV2

  2016cited by this paper
• Chlorotoxin: Structure, activity, and potential uses in cancer therapy

  2016cited by this paper
• Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti–Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis

  2015cited by this paper
• Cystine-knot peptides: emerging tools for cancer imaging and therapy

  2014cited by this paper
• Disulfide-rich macrocyclic peptides as templates in drug design.

  2014cited by this paper
• Thematic Minireview Series on Circular Proteins

  2012cited by this paper
• Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies

  2012cited by this paper
• PET Imaging of CXCR4 Receptors in Cancer by a New Optimized Ligand

  2011cited by this paper
• Engineered Single-Domain Antibodies with High Protease Resistance and Thermal Stability

  2011cited by this paper
• Somatostatin Receptors as Targets for Nuclear Medicine Imaging and Radionuclide Treatment

  2011cited by this paper
• Functional Mutation of Multiple Solvent-Exposed Loops in the Ecballium elaterium Trypsin Inhibitor-II Cystine Knot Miniprotein

  2011cited by this paper
• Pharmacokinetically Stabilized Cystine Knot Peptides That Bind Alpha-v-Beta-6 Integrin with Single-Digit Nanomolar Affinities for Detection of Pancreatic Cancer

  2011cited by this paper
• Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy.

  2011cited by this paper
• Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention

  2010cited by this paper
• Evaluation of a 64Cu-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for PET of Tumors Expressing αvβ3 Integrin

  2010cited by this paper
• Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 1 – molecular pathways

  2010cited by this paper
• A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects.

  2010cited by this paper
• Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low‐nanomolar affinity

  2009cited by this paper
• Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities.

  2009cited by this paper
• Synthesis and characterization of a high-affinity αvβ6-specific ligand for in vitro and in vivo applications

  2009cited by this paper
• Albumin as Fatty Acid Transporter

  2008cited by this paper
• Therapeutic radionuclides: biophysical and radiobiologic principles.

  2008cited by this paper
• A Peptide Selected by Biopanning Identifies the Integrin αvβ6 as a Prognostic Biomarker for Nonsmall Cell Lung Cancer

  2007cited by this paper
• Use of a peptide derived from foot-and-mouth disease virus for the noninvasive imaging of human cancer: generation and evaluation of 4-[18F]fluorobenzoyl A20FMDV2 for in vivo imaging of integrin alphavbeta6 expression with positron emission tomography.

  2007cited by this paper
• Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci.

  2007cited by this paper
• Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond

  2007cited by this paper
• Strategies to improve plasma half life time of peptide and protein drugs

  2006cited by this paper
• Quantitative PET Imaging of Tumor Integrin αvβ3 Expression with 18F-FRGD2

  2006cited by this paper
• Polymer-drug conjugates: Progress in polymeric prodrugs

  2006cited by this paper
• The cyclotide family of circular miniproteins: nature's combinatorial peptide template.

  2006cited by this paper
• PEGylation, successful approach to drug delivery.

  2005cited by this paper
• Structural and Kinetic Analysis of the Substrate Specificity of Human Fibroblast Activation Protein α*

  2005cited by this paper
• The Proteolytic Stability of ‘Designed’ β‐Peptides Containing α‐Peptide‐Bond Mimics and of Mixed α,β‐Peptides: Application to the Construction of MHC‐Binding Peptides

  2005cited by this paper
• Imaging glioma extent with 131I-TM-601.

  2005cited by this paper
• [18F]Galacto-RGD: synthesis, radiolabeling, metabolic stability, and radiation dose estimates.

  2004cited by this paper
• Antibody pharmacokinetics and pharmacodynamics.

  2004cited by this paper
• Tyr3-Octreotide and Tyr3-Octreotate Radiolabeled with 177Lu or 90Y: Peptide Receptor Radionuclide Therapy Results In Vitro

  2003cited by this paper
• Contents of Next Issues · Themenvorschau

  2002cited by this paper
• The Outstanding Biological Stability of β‐ and γ‐Peptides toward Proteolytic Enzymes: An In Vitro Investigation with Fifteen Peptidases

  2001cited by this paper
• [177Lu‐DOTA0,Tyr3]octreotate for somatostatin receptor‐targeted radionuclide therapy

  2001cited by this paper
• Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

  2000cited by this paper
• Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif.

  1999cited by this paper
• Prostate-specific membrane antigen expression in normal and malignant human tissues.

  1997cited by this paper
• Comparison of the proteolytic susceptibilities of homologous L‐amino acid, D‐amino acid, and N‐substituted glycine peptide and peptoid oligomers

  1995cited by this paper
• Molecular cloning of fibroblast activation protein alpha, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers.

  1994cited by this paper
• Conformational restrictions of biologically active peptides via amino acid side chain groups.

  1982cited by this paper

• No citing papers are available for this paper.